Our results strongly suggest that treatment with a LRRK2 inhibitor may not befit PD patients carrying mutations in both the GBA1 and the LRRK2 genes and might even worsen the severity of parkinsonian symptoms, as was previously addressed [63]. The gene discussed is LRRK2; the disease is Parkinson disease.